Metabolic effects of metformin in patients with impaired glucose tolerance
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims To assess the effect of metformin on insulin sensitivity, glucose tolerance and components of the metabolic syndrome in patients with impaired glucose tolerance (IGT). Methods Forty first‐degree relatives of patients with Type 2 diabetes fulfilling WHO criteria for IGT and participating in the Botnia study in Finland were randomized to treatment with either metformin 500 mg b.i.d. or placebo for 6 months. An oral glucose tolerance test (OGTT) and a euglycaemic hyperinsulinaemic clamp in combination with indirect calorimetry was performed at 0 and 6 months. The patients were followed after stopping treatment for another 6 months in an open trial and a repeat OGTT was performed at 12 months. Results Metformin treatment resulted in a 20% improvement in insulin‐stimulated glucose metabolism (from 28.7 ± 13 to 34.4 ± 10.7 µmol/kg fat‐free mass (FFM)/min) compared with placebo (P = 0.01), which was primarily due to an increase in glucose oxidation (from 16.6 ± 3.6 to 19.1 ± 4.4 µmol/kg FFM; P = 0.03) These changes were associated with a minimal improvement in glucose tolerance, which was maintained after 12 months. Conclusions Metformin improves insulin sensitivity in subjects with IGT primarily by reversal of the glucose fatty acid cycle. Obviously large multicentre studies are needed to establish whether these effects are sufficient to prevent progression to manifest Type 2 diabetes and associated cardiovascular morbidity and mortality. Diabet. Med. 18, 578–583 (2001)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Warram, J. H., Martin, B. C., Krolewski, A. S., Soeldner, J. S., & Kahn, C. R. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-12-909 · Cited by 1,038
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807
Self-citationEfficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Groop, L. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.737 · Cited by 408
Self-citationMechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408
GROOP, L. C., SALORANTA, C., SHANK, M., BONADONNA, R. C., FERRANNINI, E., & DEFRONZO, R. A. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-96 · Cited by 312
Self-citation
Cited by
Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes
I. S. Sobczak, A., A. Blindauer, C., & J. Stewart, A. (2019) · Nutrients · doi:10.3390/nu11092022 · Cited by 304
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
The Diabetes Prevention Program Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.4.977 · Cited by 218
“(4) reported that treatment with metformin resulted in an improvement in glucose tolerance that lasted for up to 6 months after cessation of metformin.”
BackgroundInterventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis
Galaviz, K. I., Weber, M. B., Suvada, K., Gujral, U. P., Wei, J., Merchant, R., Dharanendra, S., Haw, J. S., Narayan, K. M. V., & Ali, M. K. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.10.020 · Cited by 149
Metadata
- Authors
- Lehtovirta, M., Forsén, B., Gullström, M., Häggblom, M., Eriksson, J. G., Taskinen, M. ‐., & Groop, L.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2001-07
- Volume
- 18
- Issue
- 7
- Pages
- 578-583
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1981101443
- Cited by
- 66
- References
- 11
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic effects of metformin in patients with impaired glucose tolerance. https://app.cochat.ai/papers/10.1046/j.1464-5491.2001.00539.x
- The paper
- Lehtovirta, M., Forsén, B., Gullström, M., Häggblom, M., Eriksson, J. G., Taskinen, M. ‐., & Groop, L. (2001). Metabolic effects of metformin in patients with impaired glucose tolerance. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.2001.00539.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.